论文部分内容阅读
目的探讨胺碘酮治疗心力衰竭合并心律失常患者的临床应用价值。方法选择2014年2月至2015年12月期间我院收治的心力衰竭合并心律失常患者74例作为研究对象,采用随机数字表法将患者分为对照组(37例)和观察组(37例),对照组给予患者常规抗心力衰竭治疗,观察组在对照组基础上增加胺碘酮治疗,对比两组患者临床疗效及不良反应发生情况。结果治疗后,观察组患者治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为13.51%,对照组不良反应发生率为16.22%,组间对比差异无统计学意义(P>0.05)。结论胺碘酮治疗心力衰竭合并心律失常患者的临床疗效显著,并且价格低廉,是一种有效的临床用药,值得临床推广。
Objective To investigate the clinical value of amiodarone in the treatment of patients with heart failure and arrhythmia. Methods Totally 74 patients with heart failure and arrhythmia received from our hospital from February 2014 to December 2015 were enrolled in this study. Patients were divided into control group (37 cases) and observation group (37 cases) by random number table. The control group was given routine anti-heart failure treatment. The observation group was given amiodarone on the basis of the control group, and the clinical efficacy and adverse reactions of the two groups were compared. Results After treatment, the total effective rate of observation group was significantly higher than that of control group (P <0.05). The incidence of adverse reactions in observation group was 13.51% and that in control group was 16.22% The difference was not statistically significant (P> 0.05). Conclusions Amiodarone treatment of patients with heart failure and arrhythmia has significant clinical efficacy and low price, which is an effective clinical medication and worthy of clinical promotion.